Andrew Saik is CFO at INTERCEPT PHARMACEUTICALS, INC. (ICPT). They have made 5 open-market trades across 2 companies since 2020, most recently 2026-06-24.
CIK 0001616284
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $58K since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EDGE | 82,999 | $4.4M |
| VYNE | 116,468 | $2.9M |
| ARVN | 187,432 | $1.3M |
| ICPT | 68,265 | $1.3M |
| MNLO | 300,000 | $405K |
| PDSB | 42,549 | $49K |
| AUXL | 10,000 | — |
| Total | $10.4M |
Shares reported on the most recent Form 4, priced at the 2026-06-24 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARVN | SELL | 2026-06-24 | 2026-06-24 | $8.16 | $46K | +6.5% | -0.4% | +5.6% |
| ARVN | SELL | 2026-05-11 | 2026-05-13 | $9.94 | $111K | -9.1% | -22.7% | -8.4% |
| ARVN | SELL | 2026-02-13 | 2026-02-18 | $11.89 | $61K | +13.5% | -7.3% | -27.6% |
| ARVN | SELL | 2025-06-24 | 2025-06-24 | $7.61 | $43K | +0.9% | +2.2% | -2.5% |
| VYNE | BUY | 2020-09-08 | 2020-09-08 | $1.46 | $58K | +23.6% | +30.4% | +14.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.